Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 7Other solid neoplasm 7Gastrointestinal 2Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Pancreatic Neoplasms 28Carcinoma, Hepatocellular 25Colorectal Neoplasms 23Carcinoma, Non-Small-Cell Lung 13Melanoma 12Stomach Neoplasms 10Colonic Neoplasms 10Liver Neoplasms 9Neoplasm Metastasis 8Squamous Cell Carcinoma of Head and Neck 7Carcinoma, Transitional Cell 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Ovarian Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Prostatic Neoplasms 5Lung Neoplasms 5Gastrointestinal Stromal Tumors 5Esophageal Neoplasms 5Carcinoma 5Urinary Bladder Neoplasms 4Turcot syndrome 4Triple Negative Breast Neoplasms 4Small Cell Lung Carcinoma 4Sarcoma 4Mesothelioma 4Endometrial Neoplasms 4Cholangiocarcinoma 4Carcinoma, Merkel Cell 4

Interventions

Cyclophosphamide 4pembrolizumab 3Nivolumab 3regorafenib 2fludarabine 2SS1(dsFv)PE38 2Ipilimumab 2Hyperthermic Intraperitoneal Chemotherapy 2Doxorubicin 2Decitabine 2Cisplatin 2tislelizumab 1sodium thiosulfate 1sargramostim 1entinostat 1durvalumab 1cemiplimab 1bemcentinib 1avelumab 1atezolizumab 1alvocidib 1alanosine 1X-Rays 1Tetrahydrouridine 1Tamoxifen 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Specimen Handling 1Referral and Consultation 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × Ipilimumab × Gastrointestinal × Clear all
NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

7 Hills Pharma, LLC

Phase 1/2 Recruiting
126 enrolled
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

Phase 1/2 Active not recruiting
57 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡